

**FORM 2**  
**THE PATENTS ACT, 1970**  
**(39 of 1970)**  
**& The Patent Rules, 2003**  
**COMPLETE SPECIFICATION**

**1. TITLE OF THE INVENTION:**

POLYMERS HAVING THERAPEUTICALLY ACTIVE AGENTS CONJUGATED THERETO,  
PROCESSES OF PREPARING SAME AND USES THEREOF

**2. APPLICANT:**

Name: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Nationality: Israel

Address: P.O. Box 39296, 6139201 Tel-Aviv, Israel.

**3. PREAMBLE TO THE DESCRIPTION:**

The following specification particularly describes the invention and the manner in which it is to be performed:

35. A pharmaceutical composition comprising, as an active ingredient, the conjugate of any of claims 1-34 and a pharmaceutically acceptable carrier.

36. The pharmaceutical composition of claim 35, being packaged in a packaging material and identified in print, in or on said packaging material, for use in the treatment of cancer or of a medical condition associated with angiogenesis.

37. The conjugate of any one of claims 1 to 34, for use in a method of treating cancer or a medical condition associated with angiogenesis.

38. A method of treating cancer or a medical condition associated with angiogenesis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the conjugate of any of claims 1-34.


39. Use of the conjugate of any one of claims 1 to 34, in the manufacture of a medicament for use in the treatment of cancer or a medical condition associated with angiogenesis.

40. The composition, conjugate, use or method of any one of claims 36-39, wherein said medical condition associated with angiogenesis is selected from the group consisting of atherosclerosis, hypertension, rheumatoid arthritis, diabetes and diabetes related complications.

41. The composition, conjugate, use or method of any one of claims 36-39, wherein said cancer is selected from the group consisting of renal cell carcinoma, Wilm's tumor, breast cancer, ovarian cancer, osteosarcoma, glioblastoma, and lung adenocarcinoma.

42. A conjugate comprising a polymeric backbone comprised of a plurality of backbone units, wherein said polymeric backbone corresponds to a polymeric backbone of polyglutamic acid and at least a portion of said backbone units has doxorubicin attached thereto through a linker that comprises a hydrazone moiety.

Dated this 10<sup>th</sup> day of September, 2014.

A handwritten signature in black ink, appearing to read 'Chetan Chadha', with a horizontal line underneath it.

(CHETAN CHADHA)  
PATENT AGENT